Enhancing personalized immune checkpoint therapy by immune archetyping and pharmacological targeting
Immune checkpoint inhibitors (ICIs) are an expanding class of immunotherapeutic agents with the potential to cure cancer. Despite the outstanding clinical response in patient subsets, most individuals become refractory or develop resistance. Patient stratification and personalized immunotherapies ar...
Saved in:
Main Authors: | Claudia Cerella (Author), Mario Dicato (Author), Marc Diederich (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combinatorial Approaches to Enhance Anti-Tumor Immunity: Focus on Immune Checkpoint Blockade Therapy
Published: (2019) -
Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
by: Gian Marco Leone, et al.
Published: (2023) -
Adoptive T cell as a strategy for targeted delivery of immune checkpoint therapy
by: J. Sung, et al.
Published: (2017) -
Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma
by: Rita Pimenta, et al.
Published: (2021) -
Editorial: Next-Generation Cancer Therapies Based on a (R)evolution of the Biomarker Landscape
by: Claudia Cerella, et al.
Published: (2022)